Ethynylcytidine,180300-43-0

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ethynylcytidine

CAS No. : 180300-43-0

MCE 国际站：Ethynylcytidine

产品活性：Ethynylcytidine (ECyD) 是一种核苷类似物，是 RNA 合成 (RNA synthesis) 的有效抑制剂，可抑制 RNA 聚合酶 I，II 和 II。Ethynylcytidine 在多种癌症模型中均具有强大的抗肿瘤活性。Ethynylcytidine 是一种点击化学试剂。它含有 Alkyne 基团，可以和含有 Azide 基团的分子发生铜催化的叠氮-炔环加成反应 (CuAAc)。

研究领域：Cell Cycle/DNA Damage

作用靶点：DNA/RNA Synthesis  |  Nucleoside Antimetabolite/Analog

In Vitro: The IC₅₀ values of Ethynylcytidine in the five human tumors with 4, 24 and 72 h exposure range from 0.114 to 1.032 μM, 0.015 to 0.067 μM, and 0.008 to 0.058 μM, respectively. These results suggest that the cytotoxicity of Ethynylcytidine tends to become stronger as the exposure time becomes longer. The differences in IC₅₀ values between the 24 and 72 h exposure times are not large, and Ethynylcytidine appeares to show sufficiently potent cytotoxicity at the 24 h exposure time in all 5 human tumors. Even at the 4 h exposure time, Ethynylcytidine clearly shows potent cytotoxicity with IC₅₀ values at submicromolar concentrations in 4 of the 5 human tumors.

In Vivo: In both OCUM-2MD3 and LX-1 xenografts, tumor regression is noted and a very potent antitumor effect with an tumor growth inhibition rate (IR) on day 15 of approximately 90% or even higher is observed at the minimum toxic doses of Ethynylcytidine (TAS-106) on all three administration schedules. In particular, administration of Ethynylcytidine at 6 mg/kg once weekly exhibits a marked tumor shrinking effect with an IR of 98% against the LX-1 tumor. While Ethynylcytidine treatment on an either 3 or 5 times weekly schedule has a potent antitumor effect with an IR of approximately 85%, the IR of Ethynylcytidine once weekly is less than 60% and its antitumor effect is rather weak.

相关产品：Covalent Screening Library Plus  |  Natural Product-like Compound Library  |  Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Reprogramming Compound Library  |  Nucleotide Compound Library  |  Anti-COVID-19 Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Heterocyclic Compound Library  |  Cycloheximide  |  Actinomycin D  |  5-Fluorouracil  |  Oxaliplatin  |  Gemcitabine  |  Decitabine  |  5-Azacytidine  |  Carboplatin  |  Bleomycin sulfate  |  Mitomycin C  |  Cytarabine  |  5-BrdU  |  Methotrexate  |  ART558  |  Streptozotocin  |  Anisomycin  |  Fludarabine  |  Thymidine  |  Hydroxyurea  |  Remdesivir  |  Daunorubicin hydrochloride  |  Brequinar  |  Capecitabine  |  Branaplam  |  α-Amanitin  |  CX-5461  |  Adenosine  |  Folic acid

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds